Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines

European Journal of Medicinal Chemistry

Volumn 96, Issue , 2015, Pages 162-172

  Salerno, Loredana ^a   Pittalà, Valeria ^a   Romeo, Giuseppe ^a   Modica, Maria N ^a   Marrazzo, Agostino ^a   Siracusa, Maria A ^a   Sorrenti, Valeria ^a   Di Giacomo, Claudia ^a   Vanella, Luca ^a   Parayath, Neha N ^b   Greish, Khaled ^b,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Anti cancer; Anti proliferative properties; Heme oxygenase; HO 1; HO 2; Inhibitors

Indexed keywords

1 [5 (4 IODOPHENOXY)PENTYL] 1H IMIDAZOLE; ALKYL GROUP; BENZOTHIAZOLE DERIVATIVE; HEME OXYGENASE 1; HEME OXYGENASE 2; HEME OXYGENASE INHIBITOR; IMIDAZOLE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HEME OXYGENASE; HEME OXYGENASE-2; HMOX1 PROTEIN, HUMAN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROPHOBICITY; LNCAP CELL LINE; MALE; MCF 7 CELL LINE; NONHUMAN; PROSTATE CANCER CELL LINE; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DOSE RESPONSE; DRUG EFFECTS; MDCK CELL LINE; METABOLISM; SYNTHESIS; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HUMANS; IMIDAZOLES; MADIN DARBY CANINE KIDNEY CELLS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84927132737     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.04.003     Document Type: Article

References (53)

1. N.G. Abraham, A. Kappas, Pharmacological and clinical aspects of heme oxygenase, Pharmacol. Rev. 60 (2008) 79-127.
2. R. Motterlini, L.E. Otterbein, The therapeutic potential of carbon monoxide, Nat. Rev. Drug Disc. 9 (2010) 728-743.
3. D.E. Baranano, M. Rao, C.D. Ferris, S.H. Snyder, Biliverdin reductase: a major physiologic cytoprotectant, Pro. Natl. Acad. Sci. U. S. A. 99 (2002) 16093-16098.
4. S.W. Ryter, J. Alam, A.M. Choi, Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications, Physiol. Rev. 86 (2006) 583-650.
5. R. Gozzelino, V. Jeney, M.P. Soares, Mechanism of cell protection by heme oxygenase-1, Annu. Rev. Pharmacol. Toxicol 50 (2010) 323-354.
6. R.J. Wong, V.K. Bhutani, H.J. Vreman, D.K. Stevenson, Tin mesoporphyrin for the prevention of severe neonatal hyperbilirubinemia, Pharmacol. Rev. 8 (2007) e77ee84.
7. L.M. Furci, P. Lopes, S. Eakanunkul, S. Zhong, A.D. MacKerell, A. Wilks, Inhibition of the bacterial heme oxygenases from Pseudomonas aeuroginosa and Neisseria meningitides: novel antimicrobial targets, J. Med. Chem. 50 (2007) 3804-3813.
8. H. Was, J. Dulak, A. Jozkowicz, Heme oxygenase-1 in tumor biology and therapy, Curr. Drug Targets 11 (2010) 1551-1570.
9. M. Mayerhofer, S. Florian, M.T. Krauth, K.J. Aichberger, M. Bilban, R. Marculescu, D. Printz, G. Fritsch, O. Wagner, E. Selzer, W.R. Sperr, P. Valent, C. Sillaber, Identification of hemoxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia, Cancer Res. 64 (2004) 3148-3154.
10. P.O. Berberat, Z. Dambrauskas, A. Gulbinas, T. Giese, N. Giese, B. Kunzli, F. Autschbach, S. Meuer, M.W. Buchler, H. Friess, Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment, Clin. Cancer Res. 11 (2005) 3790-3798.
11. J. Fang, T. Sawa, T. Akaike, T. Akuta, S.K. Sahoo, K. Greish, A. Hamada, H. Maeda, In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor, Cancer Res. 63 (2003) 3567-3574.
12. L. Vanella, C. Di Giacomo, R. Acquaviva, I. Barbagallo, G. Li Volti, V. Cardile, N.G. Abraham, V. Sorrenti, Effects of Ellagic Acid on Angiogenic Factors in Prostate Cancer Cells, Cancers (Basel) 5 (2013) 726-738.
13. J.Z. Vlahakis, R.T. Kinobe, R.J. Bowers, J.F. Brien, K. Nakatsu, W.A. Szarek, Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors, Bioorg. Med. Chem. Lett. 15 (2005) 1457-1461.
14. V. Pittal-a, L. Salerno, G. Romeo, M.N. Modica, M.A. Siracusa, A focus on heme oxygenase-1 (HO-1) and its inhibitors, Curr. Med. Chem. 20 (2013) 3711-3732.
15. M.N. Rahman, J.Z. Vlahakis, G. Roman, D. Vukomanovic, W.A. Szarek, K. Nakatsu, Z. Jia, Structural characterization of human heme oxygenase-1 complex with azole-based inhibitors, J. Inorg. Biochem. 104 (2010) 324-330.
16. M.N. Rahman, D. Vukomanovic, J.Z. Vlahakis, W.A. Szarek, K. Nakatsu, Z. Jia, Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds, J. R. Soc. Interface 10 (2013) 1-14.
17. V. Sorrenti, S. Guccione, C. Di Giacomo, M.N. Modica, V. Pittal-a, R. Acquaviva, L. Basile, M. Pappalardo, L. Salerno, Evaluation of imidazole-based compounds as heme oxygenase-1 inhibitors, Chem. Biol. Drug Des. 80 (2012) 876-886.
18. L. Salerno, V. Pittal-a, G. Romeo, M.N. Modica, M.A. Siracusa, C. Di Giacomo, R. Acquaviva, I. Barbagallo, D. Tibullo, V. Sorrenti, Evaluation of novel aryloxyalkyl derivatives of imidazole and 1, 2, 4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties, Bioorg. Med. Chem. 21 (2013) 5145-5153.
19. M.A. Alaoui-Jamali, T.A. Bismar, A. Gupta, W.A. Szarek, J. Su, W. Song, Y. Xu, B. Xu, G. Liu, J.Z. Vlahakis, G. Roman, J. Jiao, H.M. Schipper, A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer, Cancer Res. 69 (2009) 8017-8024.
20. L. Salerno, M.N. Modica, G. Romeo, V. Pittal-a, M.A. Siracusa, M.E. Amato, R. Acquaviva, C. Di Giacomo, V. Sorrenti, Novel inhibitors of nitric oxide synthase with antioxidant properties, Eur. J. Med. Chem. 49 (2012) 118-126.
21. L. Salerno, V. Sorrenti, F. Guerrera, M.C. Sarv-a, M.A. Siracusa, C. Di Giacomo, A. Vanella, N-substituted imidazoles as inhibitors of nitric oxide synthase, a preliminary screening, Pharmazie 54 (1999) 685-690.
22. C. Di Giacomo, V. Sorrenti, L. Salerno, V. Cardile, F. Guerrera, M.A. Siracusa, M. Avitabile, A. Vanella, Novel inhibitors of neuronal nitric oxide synthase, Exp. Biol. Med. 228 (2003) 486-490.
23. C. Walz, M. Sattler, Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML), Crit. Rev. Oncol. Hematol. 57 (2006) 145-164.
24. M. Mayerhofer, K.V. Gleixner, J. Mayerhofer, G. Hoermann, E. Jaeger, K.J. Aichberger, R.G. Ott, K. Greish, H. Nakamura, S. Derdak, P. Samorapoompichit, W.F. Pickl, V. Sexl, H. Esterbauer, I. Shwarzinger, C. Sillaber, H. Maeda, P. Valent, Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib, Blood 111 (2008) 2200-2210.
25. R. Kondo, K.V. Gleixner, M. Mayerhofer, A. Vales, A. Gruze, P. Samorapoompichit, K. Greish, M.T. Krauth, K.J. Aichberger, W.F. Pickl, H. Esterbauer, C. Sillaber, H. Maeda, P. Valent, Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells, Blood 110 (2007) 661-669.
26. M.N. Rahman, J.Z. Vlahakis, W.A. Szarek, K. Nakatsu, Z. Jia, X-ray crystal structure of human heme oxygenase-1 in complex with 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone: a common binding mode for imidazole-based heme oxygenase-1 inhibitors, J. Med. Chem. 51 (2008) 5943-5952.
27. S. Bondock, W. Fadaly, M.A. Metwally, Synthesis and antimicrobial activity of some new thiazole, thiophene and pyrazole derivatives containing benzothiazole moiety, Eur. J. Med. Chem. 45 (2010) 3692-3701.
28. S.T. Huang, I.J. Hsei, C. Chen, Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles, Bioorg. Med. Chem. 14 (2006) 6106-6119.
29. C.J. Lion, C.S. Matthews, G. Wells, T.D. Bradshaw, M.F.G. Stevens, A.D. Westwell, Antitumour properties of fluorinated benzothiazolesubstituted hydroxycyclohexa-2, 5-dienones ('quinols'), Bioorg. Med. Chem. Lett. 16 (2006) 5005-5008.
30. H.L.K. Stanton, R. Gambari, C.H. Chui, M.C. Yuen, E. Lin, R.S.M. Wong, F.Y. Lau, G.Y.M. Cheng, W.S. Lam, S.H. Chan, K.H. Lam, C.H. Cheng, P.B.S. Lai, M.W.Y. Yu, F. Cheung, J.C.O. Tang, A.S.C. Chan, Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines, Bioorg. Med. Chem. 16 (2008) 3626-3631.
31. S. Pattan, C. Suresh, V. Pujar, V. Reddy, V. Rasal, B. Koti, Synthesis and antidiabetic activity of 2-amino [500(4-sulphonylbenzylidine)-2, 4-thiazolidinenone]-7-chloro-6-flurobenzothiazole, Ind. J. Chem. 44B (2005) 2404-2408.
32. J. Poupaert, P. Carato, E. Colacino, 2(3H)-benzoazolone and bioisosters as "privileged scaffold" in the design of pharmacological probes, Curr. Med. Chem. 12 (2005) 877-885.
33. J.Z. Vlahakis, D. Vukomanovic, K. Nakatsu, W.A. Szarek, Selective inhibition of heme oxygenase-2 activity by analogs of 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole (clemizole): exploration of the effects of the substituents at the N-1 position, Bioorg. Med. Chem. 21 (2013) 6788-6795.
34. F.H. Bai, N.N. Qi, C.X. Wu, Y.Z. Nie, A new insight into the effect of heme oxygenase-1 in progress of malignant tumors, J. Gastroen. Hepatol. Res. 2 (2013) 353-358.
35. QikProp, Version 4.3, Schrodinger, LLC, New York, NY, 2015.
36. W.Y. Lee, Y.C. Chen, C.M. Shih, C.M. Lin, C.H. Cheng, K.C. Chen, C.W. Lin, The induction of heme oxygenase-1 suppresses heat shock protein and the proliferation of human breast cancer cells through its by product carbon monoxide, Toxicol. Appl. Pharm. 274 (2014) 55-62.
37. D.H. Kim, J.H. Kim, E.H. Kim, H.K. Na, Y.N. Cha, J.H. Chung, Y.J. Surh, 15-deoxy-D12, 14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS, Carcinogenesis 30 (2009) 645-654.
38. M. Hill, V. Pereira, C. Chauveau, R. Zagani, S. Remy, L. Tesson, D. Mazal, L. Ubillos, R. Brion, K. Ashgar, M.F. Mashreghi, K. Kotsch, J. Moffett, C. Doebis, M. Seifert, J. Boczkowski, E. Osinaga, I. Anegon, Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2, 3-dioxygenase, FASEB J. 19 (2005) 1957-1968.
39. P. Bahmani, G. Hassanshahi, R. Halabian, A.M. Roushandeh, A. Jahanian-Najafabadi, M.H. Roudkenar, The expression of heme oxygenase-1 in humanderived cancer cell lines, Iran. J. Med. Sci. 36 (2011) 260-265.
40. S.Y.M.L. Jin, Y.H. Kim, S.J. Lee, G. Park, Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression, Oncol. Rep. 31 (2014) 497-504.
41. C.W. Lin, S.C. Shen, W.C. Hou, L.Y. Yang, Y.C. Chen, Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase, Mol. Cancer. Ther. 7 (2008) 1195-1206.
42. S.J. Noh, J.S. Bae, U. Jamiyandorj, H.S. Park, K.S. Kwon, S.H. Jung, H.J. Youn, H. Lee, B.H. Park, M.J. Chung, W.S. Moon, M.J. Kang, K.Y. Jang, Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients, BMC Cancer 13 (2013) 516.
43. P. Sacca, R. Meiss, G. Casas, O. Mazza, J.C. Calvo, N. Navone, E. Vazquez, Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer, Brit. J. Cancer 97 (2007) 1683-1689.
44. G. Gueron, A. De Siervi, M. Ferrando, M. Salierno, P. De Luca, B. Elguero, R. Meiss, N. Navone, E.S. Vazquez, Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells, Mol. Cancer Res. 7 (2009) 1745-1755.
45. M. Linnenbaum, M. Busker, J.R. Kraehling, S. Behrends, Heme oxygenase isoforms differ in their subcellular trafficking during hypoxia and are differentially modulated by cytochrome P450 reductase, PLoS One 7 (2012) e35483.
46. F. Namba, H. Go, J.A. Murphy, P. La, G. Yang, S. Sengupta, A.P. Fernando, M. Yohannes, C. Biswas, S.L. Wehrli, P.A. Dennery, Expression level and subcellular localization of heme oxygenase-1 modulates its cytoprotective properties in response to lung injury: a mouse model, PLoS One 9 (2014) e90936.
47. D. Tibullo, I. Barbagallo, C. Giallongo, P. La Cava, N. Parrinello, L. Vanella, F. Stagno, G.A. Palumbo, G. Li Volti, F. Di Raimondo, Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells, Curr. Pharm. Res. 19 (2013) 2765-2770.
48. J.Z. He, J.J. Ho, S. Gingerich, D.W. Courtman, P.A. Marsden, M.E. Ward, Enhanced translation of heme oxygenase-2 preserves human endothelial cell viability during hypoxia, J. Biol. Chem. 285 (2010) 9452-9461.
49. R.A.W. Johnstone, M.E. Rose, A rapid, simple, and milde procedure for alkylation of phenols, alchools, amides and acids, Tetrahedron 35 (1979) 2169-2173.
50. M.A. Siracusa, L. Salerno, M.N. Modica, V. Pittal-a, G. Romeo, M.E. Amato, M. Nowak, A.J. Bojarski, I. Mereghetti, A. Cagnotto, T. Mennini, Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands, J. Med. Chem. 51 (2008) 4529-4538.
51. A. Khalafi-Nezhad, M.N. Soltani Rad, H. Mohabatk-ar, Z. Asrari, B. Hemmateenejad, Design, synthsesis, antibacterial and QSAR studies of benzimidazole and imidazole chloroaryloxyalkyl derivatives, Bioorg. Med. Chem. 13 (2005) 1931-1938.
52. O.H. Lowry, N.J. Rosenbrough, A.J. Farr, R.G. Randall, Protein measurement with the folin phenol reagent, J. Biol. Chem. 193 (1951) 265-275.
53. V. Vichai, K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity screening, Nat. Protoc. 1 (2006) 1112-1116.